Nuvaxovid 2026-27 Injection, Suspension
Product Images NDC 49281-026

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Nuvaxovid 2026-27 (NDC 49281-026). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi Vaccines Us Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (0.5 mL Syringe Label)

Label of NUVAXOVID 2026-27 COVID-19 Vaccine, Adjuvanted, showing the brand name Nuvaxovid and the 2026-2027 formula. The label includes a barcode, lot number and expiration date fields (blank), and the labeler Sanofi Vaccines US Inc. The label indicates the vaccine component and product identification details.*

FDA Label Image

Principal Display Panel (0.5 mL Syringe Carton)

Packaging label for NUVAXOVID 2026-27 Formula COVID-19 Vaccine, Adjuvanted by Sanofi Vaccines US Inc. The label states the product is for intramuscular use and includes 10 single-dose pre-filled syringes, each containing 1 dose of 0.5 mL. It is intended for people 65 years and older and for those 12 through 64 years at high risk for severe COVID-19. Storage instructions specify refrigeration between 2°C to 8°C and protection from light, with a caution to not freeze. The label also notes it contains no preservative and latex-free components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.